Molecular characterization and substrate identification of malaria kinase PfCDPK5
疟疾激酶 PfCDPK5 的分子表征和底物鉴定
基本信息
- 批准号:8525534
- 负责人:
- 金额:$ 43.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-12-15 至 2017-11-30
- 项目状态:已结题
- 来源:
- 关键词:Age-YearsAntimalarialsBindingBiological ProcessBloodCalciumCalcium BindingCandidate Disease GeneCellsCessation of lifeChildChild MortalityClinicalDeveloping CountriesDevelopmentDiseaseEpitopesErythrocytesEssential GenesEvaluationFutureGeneticGoalsHumanHuman GenomeIn VitroInfectionInvestigationLifeLife Cycle StagesLongitudinal StudiesMalariaMediator of activation proteinMolecularMolecular GeneticsMorbidity - disease rateParasitesPeptide HydrolasesPharmaceutical PreparationsPhosphorylationPhosphotransferasesPlasmodiumPlasmodium falciparumPregnant WomenProcessProteinsProteomicsPublic HealthRecombinantsRegulationResistanceResourcesRoleSignal PathwaySignal TransductionStagingSystemTarsTechniquesTertiary Protein StructureTherapeuticTimeToxoplasma gondiiTransgenic OrganismsVaccinesYeastsanalogasexualbaseburden of illnesscalcium-dependent protein kinasecombatdesignfallsgenetic analysisknock-downmembermortalitymutantnovelpreventpublic health relevancetoolvector controlyeast two hybrid system
项目摘要
DESCRIPTION (provided by applicant): Malaria is among the leading causes of mortality for children under five years of age worldwide, with most of these deaths resulting from Plasmodium falciparum infection. Resistance to existing anti-malarial medications is an urgent problem and may prevent effective eradication strategies. A molecular understanding of the life cycle of P. falciparum will facilitate the rational design of new therapies. Efficient egress of P.
falciparum out of an infected human red blood cell is a fundamental step in the parasite life cycle, and a step that is not targeted by current anti-malarial therapeutics. PfCDPK5 has recently been identified as a kinase that is critical for parasite egress. Using a state-of-the-art
inducible protein destabilization system, functional evaluation of this essential gene is now possible. Transgenic parasites with an inducible knockdown in PfCDPK5 are arrested prior to egress. The ability to regulate the level of PfCDPK5 provides a unique resource to study both the mechanism of activation and the downstream effectors of this essential kinase. We hypothesize that PfCDPK5 is a central mediator of the calcium-based egress signaling pathway. The immediate goals of this proposal are to gain a molecular understanding of PfCDPK5 activation and characterize its role in the egress signaling pathway. In the first aim, a molecular
genetic analysis of PfCDPK5 activation will be conducted using transgenic parasites that allow inducible regulation of essential protein levels. In the second aim, the downstream substrate(s) of PfCDPK5 will be discovered using both a candidate gene approach as well as advanced proteomic techniques. The long- term objectives and public health implications of these studies are to identify novel targets for new anti- malarial therapeutics. This long-term goal will be achieved as a direct result from the molecular characterization of the essential PfCDPK5 signaling pathway in P. falciparum parasites.
描述(由申请人提供):疟疾是全世界五岁以下儿童死亡的主要原因之一,其中大多数死亡是由恶性疟原虫感染造成的。对现有抗疟疾药物的耐药性是一个紧迫的问题,可能妨碍有效的根除策略。对恶性疟原虫生命周期的分子理解将有助于合理设计新的治疗方法。P的有效输出。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY D DVORIN其他文献
JEFFREY D DVORIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY D DVORIN', 18)}}的其他基金
Functional characterization of striated fiber assemblins in malaria parasites
疟疾寄生虫中横纹纤维组装体的功能特征
- 批准号:
10675782 - 财政年份:2023
- 资助金额:
$ 43.79万 - 项目类别:
Functional investigation of a novel and essential subcellular compartment in Plasmodium falciparum transmission stage parasites
恶性疟原虫传播阶段寄生虫中新型重要亚细胞区室的功能研究
- 批准号:
10458816 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Functional investigation of a novel and essential subcellular compartment in Plasmodium falciparum transmission stage parasites
恶性疟原虫传播阶段寄生虫中新型重要亚细胞区室的功能研究
- 批准号:
10584525 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Molecular mechanisms of schizogony in malaria parasites
疟原虫分裂的分子机制
- 批准号:
10620476 - 财政年份:2019
- 资助金额:
$ 43.79万 - 项目类别:
Molecular mechanisms of schizogony in malaria parasites
疟原虫分裂的分子机制
- 批准号:
10161727 - 财政年份:2019
- 资助金额:
$ 43.79万 - 项目类别:
Molecular mechanisms of schizogony in malaria parasites
疟原虫分裂的分子机制
- 批准号:
10627871 - 财政年份:2019
- 资助金额:
$ 43.79万 - 项目类别:
Molecular mechanisms of schizogony in malaria parasites
疟原虫分裂的分子机制
- 批准号:
9797203 - 财政年份:2019
- 资助金额:
$ 43.79万 - 项目类别:
Molecular mechanisms of schizogony in malaria parasites
疟原虫分裂的分子机制
- 批准号:
10407023 - 财政年份:2019
- 资助金额:
$ 43.79万 - 项目类别:
Essential gene discovery in the malaria parasite Plasmodium falciparum
疟原虫恶性疟原虫中重要基因的发现
- 批准号:
8564839 - 财政年份:2013
- 资助金额:
$ 43.79万 - 项目类别:
Molecular analysis of a kinase essential for replication of Plasmodium falciparum
恶性疟原虫复制所必需的激酶的分子分析
- 批准号:
7868632 - 财政年份:2010
- 资助金额:
$ 43.79万 - 项目类别:
相似海外基金
Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
- 批准号:
MR/X030202/1 - 财政年份:2023
- 资助金额:
$ 43.79万 - 项目类别:
Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
- 批准号:
10742205 - 财政年份:2023
- 资助金额:
$ 43.79万 - 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
- 批准号:
10635649 - 财政年份:2023
- 资助金额:
$ 43.79万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10534667 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10533634 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
- 批准号:
2749037 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
- 批准号:
468862 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
- 批准号:
10646331 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
- 批准号:
10368441 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
- 批准号:
10663334 - 财政年份:2022
- 资助金额:
$ 43.79万 - 项目类别:














{{item.name}}会员




